MedTrace Logo

The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein

NCT02562183 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2186

Last updated 2018-01-17

No results posted yet for this study

Summary

In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to real clinical practice (suggest above 14days treatment) and 90 days follow up

Conditions

  • Cerebral Infarction

Interventions

DRUG

kallikrein

Using kallikrein

Sponsors & Collaborators

  • Techpool Bio-Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liying Cui, Doctor · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02562183 on ClinicalTrials.gov